Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

30 Apr 2019

Abstract excerpt

BACKGROUND: Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patients, though this does not detect somatic variants. We assessed the feasibility of a workflow for universal tumor DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31076742
DOI: 10.1093/jnci/djz080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionPMID 31076742Read ↗

Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.Semantic proximity Read ↗

Opportunities to improve detection of genetic predisposition for ovarian cancer applying the Tumor-First workflow.Semantic proximity Read ↗

Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow.Semantic proximity Read ↗

Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.Semantic proximity Read ↗

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).Semantic proximity Read ↗

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer PatientsSemantic proximity Read ↗

BRCA mutations: Implications of genetic testing in ovarian cancer.Semantic proximity Read ↗

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionSemantic proximity Read ↗

Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.Semantic proximity Read ↗

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor TherapySemantic proximity Read ↗

Genetic testing for epithelial ovarian cancer.Semantic proximity Read ↗

[Genetic testing in epithelial ovarian cancer: implementation of the 'Tumor-First' workflow].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.